Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Michael Dennis, MD, Nigel H. Russell, MD, Nicki Panoskaltsis, MD, Claire Jane Hemmaway, MD, Donald Milligan, MD, Richard E Clark, MBBS MD, Robert K. Hills, MA MSc DPhil, Alan K Burnett, MD

Blood (2014) 124 (21): 3747.

https://doi.org/10.1182/blood.V124.21.3747.3747

Published: 2014

Journal Articles

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Alan K Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jamie Cavenagh, Jonathan Kell, MD MB, Gail Jones, Asim Khwaja, FRCPath, Mary Frances McMullin, MDFRCPath,FRCP, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 2308.

https://doi.org/10.1182/blood.V124.21.2308.2308

Published: 2014

Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD

Blood (2014) 124 (21): 1109.

https://doi.org/10.1182/blood.V124.21.1109.1109

Published: 2014

Journal Articles

Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML

Ross Kinstrie, PhD BSc, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, BSc, Richard E Clark, MBBS MD, Paresh Vyas, Mhairi Copland, PhD BSc, MRCP, FRCPath

Blood (2014) 124 (21): 3489.

https://doi.org/10.1182/blood.V124.21.3489.3489

Published: 2014

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, MD, Timothy P. Hughes, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Hirohisa Nakamae, MD, PhD, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, Gabriel Etienne, MD, PHD, Ian Flinn, MD, PhD, Jeffrey H. Lipton, MD, PhD, Ricardo Pasquini, MD, PhD, Beatriz Moiraghi, MD, Charisse Kemp, Xiaolin Fan, PhD, Hans D. Menssen, MD, PhD, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 92.

https://doi.org/10.1182/blood.V122.21.92.92

Published: 2013

Journal Articles

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Nigel Russell, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, David Bowen, MD, PhD, Mary Frances McMullin, MD

Blood (2013) 122 (21): 358.

https://doi.org/10.1182/blood.V122.21.358.358

Published: 2013

Journal Articles

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Blood (2013) 122 (21): 1469.

https://doi.org/10.1182/blood.V122.21.1469.1469

Published: 2013

Journal Articles

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Alan K. Burnett, MD, David Bowen, MD, PhD, Nigel Russell, MD, Steven Knapper, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Asim Khwaja, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Dominic Culligan, Helen Clark, Robert K. Hills, MA, MSc, DPhil

Blood (2013) 122 (21): 622.

https://doi.org/10.1182/blood.V122.21.622.622

Published: 2013

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

NARROW

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only